Introduction
The incidence of adenocarcinoma of the uterine cervix has increased since the 1970's, particularly among young women in Japan1). Adenocarcinomas currently account for 20-25% of all cervical cancers2). High-risk types of human papillomavirus (HPV) play an important role in the carcinogenesis of cervical adenocarcinomas and are detected in 4394% of adenocarcinomas3). HPV oncoproteins E6 and E7 inactivate the tumor suppressor proteins p53 and retinoblastoma protein (pRb) that maintain tightly regulated cell proliferation and growth. When the control mechanisms of the cell cycle are disturbed, unrestricted cell proliferation results in tumor development. P16 is one of the cyclin-dependent kinase (CdK) inhibitory proteins that decelerate the cell cycle by inactivating the CdKs that phosphorylate pRb. Because p16 underlies a negative feedback control by pRb, inactivation of pRb by HPV or through mutations may result in an overexpression of p16 and dysregulation of CdK4 and CdK6. Ishikawa et al reported that overexpression of p16 may be an indication of the pathogenic activity of high-risk types of HPV4). In the present study, we have used immunohistochemistry to test whether p16, another cell cycle protein (p53), and a cell proliferation marker (Ki-67) are overexpressed in cervical adenocarcinomas, and we examined the possible correlation between the overexpression of these proteins and the presence of HPV-DNA [measured by in situ hybridization (ISH) and polymerase chain reaction (PCR)] . We also analyzed the possible correlation between the expression of these proteins, HPV-DNA positivity, and the clinicopathological factors in 50 stages Ib and II cases (tumors limited to the uterine cervix with or without parametrial invasion) assessed in accordance with the staging established by the International Federation of Gynecology and Obstetrics.
Materials and Methods

Patients
This study included 68 Japanese women with cervical adenocarcinomas distributed as follows ; 38 patients had mucinous adenocarcinomas (28 endocervical type, 1 minimal deviation, 2 villoglandular papillary, and 7 intestinal-type adenocarcinomas), 7 patients had endometrioid adenocarcinoma, 2 patients had clear-cell adenocarcinoma, 3 patients had mixed adenocarcinomas, 8 patients had adenocarcinoma in situ (AIS), and 10 patients had adenosquamous carcinoma. The patients were treated in the Department of Obstetrics and Gynecology of Showa University Hospital and related hospitals. The patients ranged in age from 30 to 77 years (mean, 48 years). The cases were staged according to the International Federation of Gynecology and Obstetrics staging system. Eight cases were stage 0, 5 cases were stage I a, 33 cases were stage Tb, 4 cases were stage ha, 13 cases were stage IIb, 4 cases were stage IIIb, and 1 case was stage IVb. Of the 13 patients with stage 0 and ha carcinomas, 3 had undergone conization and 10 had had a hysterectomy. Of the 50 patients with stage Ib and stage II carcinomas, 42 had undergone radical hysterectomy, 2 had undergone subradical hysterectomy, and 4 had undergone simple abdominal total hysterectomy ; details for the remaining 2 cases are not known. Pelvic lymphadenectomy was performed in 46 of the 50 patients with stages I b and stage II carcinomas. Two of the 5 patients with stages III and stage IV carcinomas underwent radical hysterectomy and the other 3 patients were given chemotherapy and radiotherapy. Patients were followed until June 2005 and 11 cases were lost to follow-up. The average follow-up period was 43.6 months (range, 2-180 months). During follow-up, no death or recurrence was observed in 12 of the 13 patients with stage 0 and stage Ia carcinomas ; we could not follow-up the remaining patient. We could follow up 41 of the 50 patients with stages Ib and stage II carcinomas ; 6 of these patients died of cancer. Three of 4 patients with stage III and stage IV carcinomas died of cancer ; we could not follow up the remaining patient. Immunohistochemical Expression and HPV Infection in Cervical Adenocarcinoma Scoring for p16-, p53-and Ki-67-positive cells.
Immunoreactivity for p16, p53, and Ki-67 was quantified as the percentage of positive tumor cells per 1000 cells counted in different areas of each section by two pathologists (A. S and M. K) independently.
With regard to immunoreactivity for p16 and Ki-67, the specimens were divided into a negative or low-expression group with less than 50% positive cells and a high-expression group with more than 50% positive cells 4, 6). With regard to immunoreactivity for p53, the specimens were divided into a negative or low-expression group with less than 25% cells with positive nuclei and a high-expression group with more than 25% cells with positive nuclei5,7). These categories were determined only according to the percentage of positive cells, regardless of the intensity of the immunohistochemical stain-
ing. According to their pattern of staining intensity, the specimens were classified as weakly, moderately or strongly positive for p16 and p53. Thus, tumors were considered weakly positive when focal tumor cells showed partial nuclear and / or cytoplasmic staining, moderately positive when diffuse tumor cells showed partial nuclear and / or cytoplasmic staining, and strongly positive when diffuse tumor cells showed global nuclear and / or cytoplasmic staining.
Detection of HPV-DNA by ISH
We used BENCHMARK (R) (fully automated slide preparation system ; Ventana Medical Systems, Tucson, AZ), which is an automated, catalyzed signal amplification system using biotinylated probes for immunochemical detection of high-risk HPV types (HPV-16, -18, -31, -33 , -35, -39, -45, -51, -52, -56, -58, -59, and -68) and low-risk HPV types (HPV-6, -11, -42, -43 , and -44), to detect HPV-DNA in formalin-fixed, paraffin-embedded tissue sections of 68 specimens. Automated processing includes baking, deparaffinization, cell conditioning, staining, and counterstaining. HPV-DNA is indicated by pale blue (low-copy number) to blueblack (high-copy number) staining of the nucleus of infected cells 8) 
Statistical Analysis
Fisher's exact test and X 2 test were used to assess for a potential association between study variables of interest in 50 of 68 stage Ib and stage II cases. P values 0.05 were considered statistically significant.
Results
Immunohistochemical staining for p16, p53, and Ki-67
Adenocarcinoma and adenosquamous carcinoma cells showed cytoplasmic and nuclear staining for p16 ( Fig. 1A) . None of the cells in normal endocervical epithelium and stroma showed a high expression of p16. The frequencies of adenocarcinomas and adenosquamous carcinomas positive for p16, p53, and Ki-67 are shown in Table 2 . Fifty-three of the 68 cases of adenocarcinomas and adenosquamous carcinomas studied (77.9%) showed a high expression of p16 (mean positive tumor cells, 76.0%; range 50-100%). All of the cases of villogulandular adenocarcinomas and adenosquamous carcinomas, and 7 of 8 (87.5%) AIS cases showed a high expression of p16. In contrast, expression of p16 in the minimal deviation adenocarcinoma specimen was low. There was no statistically significant difference among histological subtypes. Of the 53 (94.3%) cases with a high expression of p16, 50 (94.3%) showed a strongly positive staining intensity for p16. Immunochemical staining for p53 was localized in the nuclei of cancer cells (Fig. 1B) . High expression of p53 was detected in 25 of the 68 cases studied (36.8%). Adenocarcinomas and adenosquamous carcinomas with a high expression of p53 showed varied weakly, moderately or strongly positive staining intensity for p53. There was no significant difference in p53 staining among histo-Immunohistochemical Expression and HPV Infection in Cervical Adenocarcinoma Fig logical types in adenocarcinomas. Immunohistochemical staining for anti-Ki-67 was localized in the nuclei of cancer cells, and occasionally, in the basal cell layers of normal mucosa (Fig.  1c ). Forty-nine of 68 cases studied (72%) showed a high expression of Ki-67. There was no statistically significant difference in Ki-67 staining among histological subtypes.
Detection of HPV DNA by ISH & PCR
ISH analysis demonstrated the presence of high-risk HPV types in 27 of the 68 tumors studied. A positive reaction was characterized by a single or multiple dot-like to diffuse signals was seen in the nuclei of cancer cells, but not in normal epithelial or stromal cells on the same slides (Fig. 2 ). Low-risk HPV types were not detected in any of the cases studied. Twenty-six of the 27 HPV-DNA-positive cases (96.2%) displayed high p16 expression, with moderately or strongly positive staining intensity. The one HPV-DNA-positive case with low expression of p16 and weakly positive staining intensity was a case of poorly differentiated endometrioid-type adenocarcinoma. Fourteen of the 41 HPV-DNA-negative cases (34.1%) showed low p16 expression. On PCR analysis, HPV-16 was detected in 9 (33.3%) and HPV-18 in 13 (48.1%) of the 27 tumors shown by ISH to be positive for HPV-DNA. One of the HPV-18-positive cases was also positive for HPV-33. HPV-16, HPV-18, or -33 were not detected in the remaining five cases shown to be HPV-DNA positive by ISH. There was no statistically significant correlation between HPV-DNA positivity and the histological subtype in the ISH or PCR studies. Table 3 shows the relationship between HPV-DNA positivity and immunohistochemical data for the 68 cases studied. There was a significant association between high expression of p16 and HPV-DNA positivity assessed by ISH (P=0.003) and PCR (P=0.001).
There was also no significant association between the high expression of Ki-67 and HPV-DNA positivity assessed by ISH (P=0.002). There was no significant relationship between the histological type and p16 expression in this study ( Table 2 ). We also found that the minimal deviation adenocarcinoma that we studied stained weakly for p16 and was HPV-DNA negative by ISH and PCR. Other studies have reported the absence or very low prevalence of HPV in this subtype 3,4). These results suggested that the development of minimal deviation adenocarcinoma might not be related to HPV infection. In contrast, villoglandular adenocarcinoma showed both a high expression of p16 with strong staining intensity, and detection of HPV-DNA positivity. Jones et al demonstrated the presence of HPV infection in 12 cases of villoglandular adenocarcinoma 14). In the present study, the two cases of villoglandular adenocarcinoma studied showed positiving for HPV-DNA by ISH and PCR. These results suggest that HPV-DNA might be more prevalent in this subtype than in other types of cervical adenocarcinoma. However, these cervical adenocarcinoma subtypes are so rare (minimal deviation adenocarcinomas account for only 1 to 3 % of cervical adenocarcinomas) that more cases need to be studied to define the relationship between minimal deviation or villoglandullar adenocarcinoma and HPV-DNA positivity.
Ishikawa et al reported that overexpression of p16 was not associated with tumor recur-rence4). These data contrast with our finding that high expression of p16 in the tumor correlated strongly with low disease recurrence (Table 4 ). Schorge et al reported that p16 does not appear to have a major role in the progression from in situ to invasive cervical carcino-ma11). Nakao et al observed a dramatic enhancement of p16 in a HPV-16 l 18-immortalized model of in situ adenocarcinoma9). This overexpression did not increased further after malignant transformation of the cells to an invasive carcinoma. These data suggest that a high expression of p16 may be observed at the early stage of the carcinogenic process, but it is not associated with the progression of cancer. The activity of p16 may be related to the low recurrence. We need to collect data on additional cases in order to discuss correlations between overexpression of Ki-67 and prognosis in cervical adenocarcinoma.
In our study, overexpression of p53, seen in 36.8% of the cervical adenocarcinomas studied, was not significantly associated with HPV-DNA positivity. Overexpression of p53 has been linked to a point mutation in the p53 gene 17). Thus, Helland et al reported a high frequency of p53 mutations (42%) in cervical cancers, and a significant association between p53 mutation and increased p53 expression18). However, some contradictory studies have demonstrated that p53 mutations are infrequent in primary cervical carcinomas, and shown that overexpression of p53 as detected by immunohistochemistry is not predictive of a somatic mutation in the p53 gene. Castren et al demonstrated that wild-type p53 may accumulate in response to DNA damage which normally leads to growth arrest or programmed cell death 19). Sahu et al reported that rearrangement of p53 correlates with increases in p53 expression at the mRNA and protein levels 17). There is no clear explanation for overexpression of p53 in the absence of a mutation in the p53 gene 19). However, overexpression of p53 may not only result from a mutation, but may also be a response to DNA damage and other unknown factors.
In this study, the incidence of HPV-DNA-positivity in the specimens studied was low, when compared to previous studies.
According to some ISH studies, high-risk HPV types can be detected in 33.6-75% of cervical adenocarcinomas 8,20-23) . We suggest two reasons for the low incidence observed in our study. First, the HPV-DNA in the specimens was present in small quantity and / or was of poor quality because of prolonged or inadequate fixation in formalin, or because the use of fixatives other than neutral buffered formalin significantly reduces the likelihood of obtaining a positive signal with ISH ; this may apply to older specimens from our laboratory. Second, we cannot rule out that the poor sensitivity of the techniques used in this study contributed to the low incidence of HPV-DNA positivity.
In summary, we have investigated the presence of HPV-DNA and the expression of proteins involved in cell cycle control or associated with cell proliferation, in cervical adenocarcinomas.
There was a strong correlation between the presence of HPV-DNA and a high expression of p16 or Ki-67. In addition, patients with a high expression of p16 had lower recurrence rates than patients with a low expression of p16, and patients with a high expression of Ki-67 had a better prognosis than patients with a low expression of Ki-67. Immunohistochemical analysis for p16 and Ki-67 is an easy procedure which might be a good screening tool for HPV infection. Demonstration of high p16 or Ki-67 expression in the specimens by immunohistochemistry was indicative of a lower recurrence rate or a better prognosis for cervical adenocarcinomas.
